ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

DYN vs BHC // EV/EBITDA & P/E VALUATION

Dyne Therapeutics Inc. (NASDAQ) VS. Bausch Health Companies Inc. (NYSE) • 15-METRIC TALLY: DYN 1 — BHC 4
■ METRIC PARITY
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (DYN VS. BHC) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC DYN BHC SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin — — — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) -35.00% 7.60% -42.60 BHC /roic <GO>
EV/EBITDA & P/E Valuation ACTIVE — 10.5x — TIE /valuation <GO>
Free Cash Flow Yield -12.73% 22.00% -34.73 BHC /fcf-yield <GO>
Operating Margin — 17.70% — TIE /operating-margins <GO>
Net Profit Margin — 1.50% — TIE /net-margins <GO>
Revenue Growth (YoY) — 6.70% — TIE /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity — 0.45 — TIE /balance-sheet <GO>
Piotroski F-Score Quality 1/9 9/9 -8.00 BHC /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 49.7 64.8 -15.10 BHC /rsi-technicals <GO>
10Y Yield & FRED Macro Beta — 0.97 — TIE /macro-sensitivity <GO>
Forward P/E Multiple — 19.7x — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $3.12B $3.07B $47.8M DYN /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR DYN REV BHC REV DYN GROSS % BHC GROSS % DYN FCF BHC FCF
FY 2025 $1.31B $10.27B — — -$405.1M $1.00B
FY 2024 $962.9M $9.63B — — -$294.7M $1.26B
FY 2023 $678.1M $8.76B — — -$188.2M $637.9M
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
DYN // BETA —
BHC // BETA 0.97